Akkermansia + butyrate OIPN — sNfL as treatment-monitoring biomarker

One-paragraph summary

Rat model of oxaliplatin-induced peripheral neuropathy (OIPN), with combined intervention of A. muciniphila + sodium butyrate. Demonstrates: (a) the combined gut-microbiome intervention attenuates OIPN behavioral pain, DRG histopathology, and intraepidermal nerve fiber density loss; (b) serum NfL operates as objective treatment-monitoring biomarker for peripheral nerve injury, with elevation in untreated OIPN and reduction following intervention. This is cross-condition methodology validation for the project's B-Re-4 bridge framing: it shows the sNfL-as-objective-readout paradigm operates outside FM, in a peripheral-nerve-injury context, with intervention sensitivity. Not FM-direct but methodologically anchor-tier for the biomarker-cohort design.

Claims as triples

• oxaliplatin — induces → peripheral_neuropathy_dose_limiting [evidence: established model; confidence: established]
• serum_NfL_level — elevated_in → oxaliplatin_induced_peripheral_neuropathy [evidence: primary measurement; confidence: emerging — rodent only]
• akkermansia_muciniphila_plus_butyrate — reduces → oipn_behavioral_pain [evidence: primary; confidence: emerging]
• akkermansia_muciniphila_plus_butyrate — reduces → serum_NfL_level_in_oipn [evidence: primary measurement; confidence: emerging]
• intraepidermal_nerve_fiber_density — reduced_by → oxaliplatin [evidence: primary IHC; confidence: established]
• intraepidermal_nerve_fiber_density — preserved_by → akkermansia_butyrate_intervention [evidence: primary IHC; confidence: emerging]
• serum_NfL_level — tracks → ienfd_loss [evidence: within-study correlation; confidence: emerging]

Methods note

Rat OIPN model induced by tail-vein oxaliplatin. Five-arm design: control, model, A. muciniphila alone, sodium butyrate (NaB) alone, combined A. muciniphila + NaB. Outcome measures: longitudinal body weight, mechanical and cold allodynia, lumbar DRG histopathology, intraepidermal nerve fiber density (IENFD) in hind paws, serum inflammatory cytokines, serum NfL. Comprehensive readout across behavior, histology, and biomarker layers.

Limitations

• Rodent model not human OIPN
• OIPN ≠ FM; mechanism overlaps may be limited
• Single oxaliplatin dose protocol; clinical OIPN has variable severity by cumulative dose
• Intervention timing relative to oxaliplatin not specified in abstract; preventive vs therapeutic timing matters
• Sample size not specified in abstract

Open questions raised

• Q-Re-21 (new): Does the sNfL-as-treatment-monitoring-biomarker paradigm transfer to FM intervention studies? FM trials historically use subjective pain scores; sNfL would provide objective monitoring if it tracks intervention response in FM as it does in OIPN.
• Q-Re-22 (new): Is the gut-microbiome → peripheral nerve injury mechanism (this paper) bidirectional with the gut-microbiome → central glial activation mechanism (reserpine-FM acetate paper)? Both implicate gut intervention but at different nerve-injury endpoints. FM may engage both arms simultaneously.

Triangulation notes

• Validates B-Re-4 methodology cross-condition: B-Re-4 framing predicts sNfL is an objective biomarker for neural-tissue injury, including peripheral. This paper demonstrates sNfL operates as a treatment-monitoring biomarker for peripheral nerve injury — directly supporting B-Re-4's claim that sNfL is a generalizable neural-injury readout, not just CNS-specific.
• Extends B2 to peripheral-nerve endpoint: B2 bridge originally framed gut-brain (CNS microglia). This paper adds gut-peripheral-nerve (DRG / IENFD) as a second endpoint. The B2 bridge can be reframed as gut → systemic-nerve (both peripheral and central), not gut-brain-only.
• Reinforces reserpine-FM acetate paper: both papers implicate gut interventions reducing pain via neuroinflammation modulation; this paper adds the peripheral component to the central component the reserpine paper anchored.
• Methodology template for FM intervention trials: trial designs for FM should consider sNfL as a primary objective outcome alongside subjective pain scores. This paper supplies the rodent-model proof-of-principle.

Bridges

• B2 reframing: bridge endpoint extended to include peripheral nerve. Update synthesis/bridges.md.
• B-Re-4 strengthening: methodology cross-condition validation. Bridge stays at emerging tier but with another anchor.

Cure-path-arm implications

• A. muciniphila + butyrate combination as candidate cure-path arm at the gut-intervention tier. Currently absent. Should be added at watchlist tier given OIPN mechanism evidence and reserpine-FM acetate convergence.
• Serum NfL as objective trial readout — methodology recommendation for future FM clinical trials.

Confidence-tier framing

• OIPN mechanism + intervention: established within rodent model
• sNfL-as-treatment-monitoring-biomarker: emerging (single study, single model)
• FM extrapolation: inferred via B2 and B-Re-4 bridges